nach oben

Erschienen in:

17.01.2022 | Original Article

miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis

verfasst von: Chaonan Zhu, Shuai Wang, Maogen Zheng, Zhiquan Chen, Guochen Wang, Jun Ma, Bin Zhang, Wuhao Huang, Xiaoyan Sun, Changli Wang, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

To clarify the modulatory mechanism of miR-31-5p in lung adenocarcinoma (LUAD) progression in vivo and in vitro.

Methods

The Cancer Genome Atlas (TCGA) database was employed to access LUAD-related miRNA and mRNA expression data. Downstream targets of miR-31-5p were predicted by public databases. The interaction between miR-31-5p and TNS1 was determined by dual-luciferase reporter assay. Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to measure miR-31-5p and TNS1 expression levels in LUAD cells. Western blot was introduced to test protein expression levels of TNS1, p53, and apoptosis-related proteins. In-vitro functional assays were conducted to evaluate the biological effects of miR-31-5p on cell proliferation, colony formation, migration, and apoptosis. In-vivo tumor xenograft experiment was applied to examine the effects of miR-31-5p on LUAD tumor growth, followed by immunochemistry assays for assessing TNS1 and p53 expression levels in the tumor tissue.

Results

miR-31-5p was prominently upregulated in LUAD tissue and was identified to present a similar trend in LUAD cell lines H1299, H23, and A549. miR-31-5p overexpression exerted an active role in cell proliferation and migration, but it suppressed cell apoptosis. Additionally, a reverse correlation between miR-31-5p and TNS1 regarding the expression level was identified, and TNS1 was verified to be a direct target of miR-31-5p. Besides, it was further validated by the rescue experiments that the tumor-promoting effects of miR-31-5p on LUAD cell functions were attenuated by TNS1 overexpression to some extent. The results based on the tumor xenograft experiment revealed that LUAD cell growth could be facilitated by miR-31-5p via the TNS1/p53 axis.

Conclusion

miR-31-5p facilitates LUAD cell progression mediated by the TNS1/p53 axis.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551CrossRefPubMed

Carrato A et al (2014) Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-lung study. Curr Med Res Opin 30:447–461. https://doi.org/10.1185/03007995.2013.860372CrossRefPubMed

Ferlay J et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937CrossRefPubMed

The Cancer Genome Atlas Research Network (2018) Author correction: comprehensive molecular profiling of lung adenocarcinoma. Nature 559:E12. https://doi.org/10.1038/s41586-018-0228-6CrossRef

Pang B et al (2017) Overexpression of RCC2 enhances cell motility and promotes tumor metastasis in lung adenocarcinoma by inducing epithelial-mesenchymal transition. Clin Cancer Res 23:5598–5610. https://doi.org/10.1158/1078-0432.CCR-16-2909CrossRefPubMed

Zheng H, Liu JY, Song FJ, Chen KX (2013) Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med 10:123–130. https://doi.org/10.7497/j.issn.2095-3941.2013.03.001CrossRefPubMedPubMedCentral

Summerer I et al (2013) Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol 8:296. https://doi.org/10.1186/1748-717X-8-296CrossRefPubMedPubMedCentral

Domingues C et al (2018) Epithelial-mesenchymal transition and microRNAs: challenges and future perspectives in oral cancer. Head Neck 40:2304–2313. https://doi.org/10.1002/hed.25381CrossRefPubMed

He J et al (2020) Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma. Int J Cancer 146:1052–1063. https://doi.org/10.1002/ijc.32543CrossRefPubMed

10.

Lu Z et al (2019) miR-31-5p is a potential circulating biomarker and therapeutic target for oral cancer. Mol Ther Nucleic Acids 16:471–480. https://doi.org/10.1016/j.omtn.2019.03.012CrossRefPubMedPubMedCentral

11.

Peng H et al (2019) MiR-31-5p promotes the cell growth, migration and invasion of colorectal cancer cells by targeting NUMB. Biomed Pharmacother 109:208–216. https://doi.org/10.1016/j.biopha.2018.10.048CrossRefPubMed

12.

Chen X et al (2019) Down-regulation of miR-31-5p inhibits proliferation and invasion of osteosarcoma cells through Wnt/beta-catenin signaling pathway by enhancing AXIN1. Exp Mol Pathol 108:32–41. https://doi.org/10.1016/j.yexmp.2019.03.001CrossRefPubMed

13.

Que KT et al (2018) MiR-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma. J Exp Clin Cancer Res 37:268. https://doi.org/10.1186/s13046-018-0930-0CrossRefPubMedPubMedCentral

14.

Borel JF (1986) Cyclosporine forever? Transplant Proc 18:271–272PubMed

15.

Lin K et al (2016) MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma. Onco Targets Ther 9:5679–5692. https://doi.org/10.2147/OTT.S111241CrossRefPubMedPubMedCentral

16.

Lin Y et al (2018) Four-miRNA signature as a prognostic tool for lung adenocarcinoma. Onco Targets Ther 11:29–36. https://doi.org/10.2147/OTT.S155016CrossRefPubMed

17.

Lv C et al (2017) MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. Nat Commun 8:1036. https://doi.org/10.1038/s41467-017-01059-5CrossRefPubMedPubMedCentral

18.

Wang N, Li Y, Zhou J (2017) miR-31 functions as an oncomir which promotes epithelial-mesenchymal transition via regulating BAP1 in cervical cancer. Biomed Res Int 2017:6361420. https://doi.org/10.1155/2017/6361420CrossRefPubMedPubMedCentral

19.

Shi J et al (2018) MiR-31 mediates inflammatory signaling to promote re-epithelialization during skin wound healing. J Invest Dermatol 138:2253–2263. https://doi.org/10.1016/j.jid.2018.03.1521CrossRefPubMedPubMedCentral

20.

Brunner M et al (2011) Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent fibronectin deposition. J Cell Biol 194:307–322. https://doi.org/10.1083/jcb.201007108CrossRefPubMedPubMedCentral

21.

Chen J (2016) The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med 6:a26104. https://doi.org/10.1101/cshperspect.a026104CrossRefPubMedPubMedCentral

22.

Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9:775–789. https://doi.org/10.1038/nrd3179CrossRefPubMedPubMedCentral

23.

Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16:203–222. https://doi.org/10.1038/nrd.2016.246CrossRefPubMed

24.

Tang C et al (2020) LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis. Aging (Albany NY) 12:25547–25563. https://doi.org/10.18632/aging.104162CrossRef

25.

Soler Artigas M et al (2011) Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function. Am J Respir Crit Care Med 184:786–795. https://doi.org/10.1164/rccm.201102-0192OCCrossRefPubMedPubMedCentral

26.

Shih YP, Sun P, Wang A, Lo SH (2015) Tensin1 positively regulates RhoA activity through its interaction with DLC1. Biochim Biophys Acta 1853:3258–3265. https://doi.org/10.1016/j.bbamcr.2015.09.028CrossRefPubMedPubMedCentral

27.

Burghel GJ et al (2013) Identification of candidate driver genes in common focal chromosomal aberrations of microsatellite stable colorectal cancer. PLoS One 8:e83859. https://doi.org/10.1371/journal.pone.0083859CrossRefPubMedPubMedCentral

Titel: miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis
verfasst von: Chaonan Zhu
Shuai Wang
Maogen Zheng
Zhiquan Chen
Guochen Wang
Jun Ma
Bin Zhang
Wuhao Huang
Xiaoyan Sun
Changli Wang, MD
Publikationsdatum: 17.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2022
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-021-01895-x

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis